High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 895-896, Issue , 2012, Pages 56-64

  Oh, Kyung Suk ^a   Park, Su Jin ^a   Shinde, Dhananjay D ^a   Shin, Jae Gook ^a   Kim, Dong Hyun ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Cocktail dosing; CYP; LC MS MS; Phenotyping; Plasma; Simultaneous analysis

Indexed keywords

COCKTAIL DOSING; CYP; LC-MS/MS; PHENOTYPING; SIMULTANEOUS ANALYSIS;

ANESTHETICS; ELECTROSPRAY IONIZATION; FORMIC ACID; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PLASMA (HUMAN); PLASMAS; POSITIVE IONS; PROBES;

BIOMOLECULES;

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ACETONITRILE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DRUG METABOLITE; FORMIC ACID; LOSARTAN; MIDAZOLAM; OMEPRAZOLE;

ACCURACY; ARTICLE; DRUG ISOLATION; DRUG STRUCTURE; ELECTROSPRAY; HIGH SENSITIVITY LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; CAFFEINE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG STABILITY; HUMANS; IMIDAZOLES; LINEAR MODELS; LIQUID-LIQUID EXTRACTION; LOSARTAN; OMEPRAZOLE; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TETRAZOLES; THEOPHYLLINE;

EID: 84860119749     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.03.014     Document Type: Article

References (20)

1. Nebert D.W., Russell D.W. Lancet 2002, 360:1155.
2. Zhang S., Song N., Li Q., Fan H., Liu C. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 871:78.
3. Xie H.G., Kim R.B. Annu. Rev. Pharmacol. Toxicol. 2001, 41:815.
4. Nafziger A.N., Bertino J.S. Clin. Pharmacol. Ther. 2007, 82:379. author reply 380.
5. Tanaka E., Kurata N., Yasuhara H. J. Clin. Pharm. Ther. 2003, 28:157.
6. Frye R.F., Matzke G.R., Adedoyin A., Porter J.A., Branch R.A. Clin. Pharmacol. Ther. 1997, 62:365.
7. Chainuvati S., Nafziger A.N., Leeder J.S., Gaedigk A., Kearns G.L., Sellers E., Zhang Y., Kashuba A.D., Rowland E., Bertino J.S. Clin. Pharmacol. Ther. 2003, 74:437.
8. Christensen M., Andersson K., Dalen P., Mirghani R.A., Muirhead G.J., Nordmark A., Tybring G., Wahlberg A., Yasar U., Bertilsson L. Clin. Pharmacol. Ther. 2003, 73:517.
9. Ryu J.Y., Song I.S., Sunwoo Y.E., Shon J.H., Liu K.H., Cha I.J., Shin J.G. Clin. Pharmacol. Ther. 2007, 82:531.
10. Fuhr U., Jetter A., Kirchheiner J. Clin. Pharmacol. Ther. 2007, 81:270.
11. Sugiyama Y., Yamashita S. Adv. Drug Deliv. Rev. 2011, 63:494.
12. Balani S.K., Nagaraja N.V., Qian M.G., Costa A.O., Daniels J.S., Yang H., Shimoga P.R., Wu J.T., Gan L.S., Lee F.W., Miwa G.T. Drug Metab. Dispos. 2006, 34:384.
13. Woelkart K.A., Kollroser M., Li L. Anal. Bioanal. Chem. 2011, 400:2371.
14. Yin O.Q., Lam S.S., Lo C.M., Chow M.S. Rapid Commun. Mass Spectrom. 2004, 18:2921.
15. Ghassabian S., Chetty M., Tattam B.N. Ther. Drug Monit. 2009, 31:239.
16. FDA Guidance for Industry Bioanalytical Method Validation May 2001, Available from:. http://www.fda.gov/.
17. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Anal. Chem. 2003, 75:3019.
18. Frerichs V.A., Zaranek C., Haas C.E. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2005, 824:71.
19. Soldner A., Spahn-Langguth H., Mutschler E. J. Pharm. Biomed. Anal. 1998, 16:863.
20. Andersin R., Mesilaakso M. J. Pharm. Biomed. Anal. 1995, 13:667.